Asset Sale
Need Based Drug Testing-AI Resistant-B2B National Accounts-Zero Labor!
Corporate Clients in Place | Fast to Launch | High-Margin B2B

$35,000,000
EBITDA: View Profit
Structural DTC Shifts Amplifying EBITDA to $5.045 Million
Financing Available
$35,000,000
EBITDA: View Profit

$6,000,000
View Profit
$6,000,000
View Profit
$1,350,000
$1,350,000


